Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Orotic acid monohydrate (2,4-dioxo-1H-pyrimidine-6-carboxylic acid hydrate) 是内源性代谢产物的一种。
产品描述 | Orotic acid monohydrate (2,4-dioxo-1H-pyrimidine-6-carboxylic acid hydrate) is an intermediate product in pyrimidine metabolism. |
体外活性 | Orotic acid increases cell proliferation and decreases apoptosis in serum-starved SK-Hep1 hepatocellular carcinoma cells, which may ascribe to the inhibition of AMP-activated protein kinase (AMPK) phosphorylation and thus activation of mammalian target of rapamycin complex 1 (mTORC1) [1]. |
体内活性 | Male Fischer 344 rats (130-150 g) to two-thirds PH in the absence or in the presence of Orotic acid (a 300-mg tablet of Orotic acid methyl ester implanted intraperitoneally at the time of two-thirds PH). treatment with Orotic acid resulted in a near-100% inhibition of RNR induced by two-thirds PH in rat liver, as monitored by enzyme activity and protein level [2]. Feeding 1% Orotic acid with diet decreased the phosphorylation of AMPK and increased the maturation of SREBP-1 and the expression of SREBP-responsive genes in the rat liver. Orotic acid-induced lipid accumulation was also completely inhibited by rapamycin. Mouse hepatocytes and mice were resistant to Orotic acid-induced lipogenesis because of little if any response in AMPK and downstream effectors [3]. |
别名 | 2,4-dioxo-1H-pyrimidine-6-carboxylic acid hydrate, Orotic Acid Monohydrate, 2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid hydrate, 乳清酸一水合物 |
分子量 | 174.11 |
分子式 | C5H6N2O5 |
CAS No. | 50887-69-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 2.5 mg/mL (14.36 mM), Sonication is recommended.
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 5.7435 mL | 28.7175 mL | 57.435 mL | 143.5874 mL |
5 mM | 1.1487 mL | 5.7435 mL | 11.487 mL | 28.7175 mL | |
10 mM | 0.5743 mL | 2.8717 mL | 5.7435 mL | 14.3587 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Orotic acid monohydrate 50887-69-9 Metabolism Others Endogenous Metabolite Orotic acid Inhibitor Orotic acid Monohydrate 2,4-dioxo-1H-pyrimidine-6-carboxylic acid hydrate Orotic Acid Monohydrate 2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid hydrate 乳清酸一水合物 2,4-dioxo-1H-pyrimidine-6-carboxylic acid Hydrate inhibit inhibitor